Cluster headache is the use case most often misunderstood, so this page is blunt: the genuinely promising cluster-headache and migraine evidence uses periodic low-to-moderate perceptible doses, not daily sub-perceptual microdosing. They are different protocols entirely. A small randomized pilot found low (but perceptible) doses reduced attack frequency, with a result that did not reach statistical significance. If you arrived from a “microdosing for cluster headaches” search, the honest answer is that the headache evidence does not run on the microdose model.
Why this matters
Cluster headache — sometimes called “suicide headache” for its severity — has one of the most compelling psilocybin stories in medicine, and it is routinely filed under microdosing where it does not belong. This page exists to set that straight while pointing to where the real evidence is. A shorter version appears in the 90-second summary on iMicrodosing.net.
Why this isn’t really a microdosing page
The established underground and trial protocol for cluster headache is a “busting” approach: a small series of perceptible doses spaced days apart, often timed to interrupt episodic cluster cycles — not a daily sub-perceptual routine. The doses involved are above the microdose threshold. It is worth being precise that cluster headache and migraine, although both severe headache disorders involving the trigeminal system, are distinct neurological disorders that differ substantially in symptoms, timing, and underlying mechanisms — so evidence for one does not automatically extend to the other. Migraine research follows a similar periodic, above-microdose pattern. So while these conditions have a real and serious psilocybin literature, that literature is describing a different intervention from the one this cluster is about. The field’s reviewers draw the same line: low-dose and larger-dose psychedelic protocols are distinct research questions, and cluster headache sits on the larger-dose side. [1] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
What the controlled study actually found
The most rigorous evidence to date is a small randomized, double-blind, placebo-controlled trial that gave 14 participants a pulse regimen of low-dose psilocybin (around 10 mg) and tracked cluster-attack frequency. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420 The treated group showed a reduction in attack frequency of roughly a third, but with so few participants the result did not reach statistical significance, and the authors present the work as exploratory groundwork for larger trials. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420 Two features matter and both distinguish this from microdosing: the dose was low but still perceptible rather than strictly sub-perceptual, and the change in attack frequency was not correlated with the intensity of any acute psychedelic effect — a dissociation that is itself a research finding worth more study. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420
- The 'busting' protocol
The cluster-headache approach is a short series of perceptible doses spaced days apart to interrupt episodic cluster cycles — periodic and above microdose, not daily and sub-perceptual. [1] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706
- Low-dose, not microdose
Even the pilot trial’s “low” dose was perceptible (around 10 mg), above the microdose threshold. Calling this work microdosing is a dose-category error. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420
- Effect uncoupled from the trip
The attack-frequency change did not track the intensity of the acute psychedelic experience — an unusual and informative dissociation that distinguishes the headache mechanism from the mood use cases. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420
Three things to keep straight
First, the real cluster-headache evidence uses periodic low-to-moderate perceptible doses, not daily microdosing. Second, even the pilot trial’s low dose was perceptible and above microdose, and its result, though encouraging, was not statistically significant. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420 Third, the headache effect appears uncoupled from the acute psychedelic experience, which both makes it scientifically interesting and further separates it from the sub-perceptual mood use cases.
Where cluster headache sits among the use cases
Cluster headache is rated moderate and tagged “distinct,” and the tag is the point. It is the one use case whose evidence comes from controlled clinical trials rather than surveys — yet that evidence is for a non-microdose protocol, so its place in a microdosing cluster is as a clarifying boundary rather than a supporting case. This dose-and-protocol distinction is the same one that organises the wider use-case literature. The controlled low-dose literature more broadly registers some real drug-versus-placebo effects, which keeps the door open for future, properly dosed headache research without retrofitting it onto microdosing. [4] Systematic review Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research doi:10.1177/02698811241254831
Is microdosing effective for cluster headaches?
The genuine cluster-headache evidence is not about microdosing. The established protocol uses periodic low-to-moderate perceptible doses spaced days apart, not daily sub-perceptual microdosing. [1] Systematic review The emerging science of microdosing: a systematic review of research on low dose psychedelics (1955-2021) and recommendations for the field doi:10.1016/j.neubiorev.2022.104706 People searching for “microdosing for cluster headaches” are usually looking for something the microdose model does not describe.
What does the actual research show?
A small randomized, placebo-controlled pilot found that low but perceptible doses reduced cluster-attack frequency by roughly a third, a result that did not reach statistical significance given the tiny sample. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420 The doses were above the microdose threshold.
Why is this different from the mood use cases?
The research uses controlled trial designs rather than surveys and uses periodic low-to-moderate perceptible doses rather than daily sub-perceptual ones. The mechanism also appears unrelated to the acute psychedelic effect. [2] Clinical trial Exploratory investigation of a patient-informed low-dose psilocybin pulse regimen in the suppression of cluster headache: results from a randomized, double-blind, placebo-controlled trial doi:10.1111/head.14420
In summary
Cluster headache has a real, serious, and scientifically intriguing psilocybin literature — and almost none of it is about microdosing. The protocol that shows promise is a periodic series of low-to-moderate perceptible doses, not a daily sub-perceptual routine; the one controlled pilot used a perceptible low dose and produced an encouraging but non-significant result; and the effect appears uncoupled from the acute experience. The accurate framing is the corrective one: this is genuine evidence for a distinct protocol, and treating it as a microdosing use case sends people toward the wrong intervention for a condition that deserves the right one.